Ovarian Cancer Update
Posted in the Ovarian Cancer Forum
Sherwood Park, Canada
#1 Apr 6, 2012
TORONTO, April 4, 2012 /CNW/- Amorfix Life Sciences Ltd. announces that it has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells. The Company's tumor-specific anti-PrP antibody was coupled to a toxic payload (urease) through collaboration with Helix Biopharma, and retained its specific binding to tumor cells without binding to normal ovarian cells.
With the establishment of proof of concept in cultured tumor cell studies, the Company will now move into the next phase of product development and evaluate the therapeutic effect of the antibody-urease conjugate for proof of concept in an animal model of cancer. The Company plans to begin these studies soon and expects to have initial results by mid August of this year.
"We have shown that the anti-PrP antibody is capable of delivering a toxic payload, in this case the molecule urease, directly to tumor cells providing a high degree of specificity with no binding to normal cells" said Amorfix President and CEO Dr. Robert Gundel. "These are very exciting and important results and represent a significant advance in the development of a novel therapeutic for the treatment of ovarian cancer."
Add your comments below
|Genetic testing lets families affected by breas...||Oct 11||Stephany McDowell||1|
|Seattle Cancer Care Alliance Opens Prostate Can...||Sep 29||Stephany McDowell||1|
|Genetics testing clinic swamped from the 'Angel...||Sep '16||Stephany McDowell||3|
|buying ed medecations (Apr '16)||Apr '16||Massey||1|
|does viagra damage the penile tissue? (Mar '16)||Apr '16||Fuentes||4|
|Can all of these symptoms be caused by ovarian ... (Sep '07)||Feb '16||lesouth||5|
|Slow start for NY's strict medical marijuana pr... (Jan '16)||Jan '16||Trucker||1|
Find what you want!
Search Ovarian Cancer Forum Now
Copyright © 2016 Topix LLC